Abstract
Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry
Highlights
Values in bold are values that are statistically significant (P value \.05)
To the Editor: Hidradenitis suppurativa (HS) patients may be at increased risk of severe COVID-19 and poor outcomes due to comorbidities and biologic treatment.[1]
COVID-19 cases in HS patients were reported in the Global Hidradenitis Suppurativa COVID-19 Registry from April 5, 2020, to February 2, 2021.1 Eligible cases had confirmed diagnosis of HS by a health care provider (HCP) or screening questions and COVID-19 diagnosis by an HCP
Summary
Values in bold are values that are statistically significant (P value \.05). Cutoff value for statistical significance #.05. To the Editor: Hidradenitis suppurativa (HS) patients may be at increased risk of severe COVID-19 and poor outcomes due to comorbidities and biologic treatment.[1] COVID-19 cases in HS patients were reported in the Global Hidradenitis Suppurativa COVID-19 Registry (https://hscovid.ucsf.edu/) from April 5, 2020, to February 2, 2021.1 Eligible cases had confirmed diagnosis of HS by a health care provider (HCP) or screening questions and COVID-19 diagnosis by an HCP.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
